Corrigendum to Incorporating new approach methodologies into regulatory nonclinical pharmaceutical safety assessment

Affiliations

¹ Safer Medicines Trust, Kingsbridge, UK.
² Animal Free Research UK, London, UK.
³ Viveo Consulting Ltd, London, UK.
⁴ Division of Biomaterials and Tissue Engineering, UCL Eastman Dental Institute, London, UK.
⁵ College of Health and Life Sciences, Aston University, Birmingham, UK.
⁶ CN Bio Innovations Limited, Cambridge, UK.
⁷ University of Exeter Medical School, Exeter, UK.
⁸ ImmuONE Limited, Hatfield, UK; Centre for Topical Drug Delivery and Toxicology, University of Hertfordshire, Hatfield, UK.
⁹ Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden; Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; University of Tübingen, Tübingen, Germany.
¹⁰ Austrian Institute of Technology GmbH, Competence Unit Molecular Diagnostics, Vienna, Austria; Department of Medicine, Danube Private University, Krems, Austria.
¹¹ Roper Toxicology Consulting Limited, Edinburgh, UK.
¹² Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, NC, USA.
¹³ Newcells Biotech, Newcastle upon Tyne, UK.
¹⁴ Cruelty Free International, London, UK.

Free article

Published Erratum

Jan Turner et al. ALTEX. 2024.

Free article

. 2024;41(4):674-675.

doi: 10.14573/altex.2408291.

¹ Safer Medicines Trust, Kingsbridge, UK.
² Animal Free Research UK, London, UK.
³ Viveo Consulting Ltd, London, UK.
⁴ Division of Biomaterials and Tissue Engineering, UCL Eastman Dental Institute, London, UK.
⁵ College of Health and Life Sciences, Aston University, Birmingham, UK.
⁶ CN Bio Innovations Limited, Cambridge, UK.
⁷ University of Exeter Medical School, Exeter, UK.
⁸ ImmuONE Limited, Hatfield, UK; Centre for Topical Drug Delivery and Toxicology, University of Hertfordshire, Hatfield, UK.
⁹ Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden; Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; University of Tübingen, Tübingen, Germany.
¹⁰ Austrian Institute of Technology GmbH, Competence Unit Molecular Diagnostics, Vienna, Austria; Department of Medicine, Danube Private University, Krems, Austria.
¹¹ Roper Toxicology Consulting Limited, Edinburgh, UK.
¹² Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, NC, USA.
¹³ Newcells Biotech, Newcastle upon Tyne, UK.
¹⁴ Cruelty Free International, London, UK.

Abstract

This corrects the article DOI: 10.14573/altex.2212081.

Incorporating new approach methodologies into regulatory nonclinical pharmaceutical safety assessment.
Turner J, Pound P, Owen C, Hutchinson I, Hop M, Chau DYS, Barrios Silva LV, Coleman M, Dubourg A, Harries LW, Hutter V, Kenna JG, Lauschke VM, Neuhaus W, Roper C, Watkins PB, Welch J, Alvarez LR, Taylor K. Turner J, et al. ALTEX. 2023;40(3):519-533. doi: 10.14573/altex.2212081. Epub 2023 Jan 18. ALTEX. 2023. PMID: 36692187